CareDx shares are trading higher after the CMS retired a draft policy that would have restricted coverage for non-invasive blood-based surveillance testing for allograft rejection.
Portfolio Pulse from Benzinga Newsdesk
CareDx shares are trading higher after the CMS retired a draft policy that would have restricted coverage for non-invasive blood-based surveillance testing for allograft rejection.
August 16, 2024 | 6:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CareDx shares are trading higher after the CMS retired a draft policy that would have restricted coverage for non-invasive blood-based surveillance testing for allograft rejection.
The retirement of the CMS draft policy removes a significant regulatory hurdle, likely leading to increased adoption and sales of CareDx's non-invasive blood-based surveillance tests. This positive regulatory development is driving the stock price higher.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100